Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy | Zendy

Walter Douthat | Zendy; Gabriela Cardozo | Zendy; Gabriela Garay | Zendy; Santiago Orozco | Zendy; Carlos Chiurchiu | Zendy; Jorge de la Fuente | Zendy; Javier de Arteaga | Zendy; P. Massari | Zendy

Open Access

Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy

Author(s) -

Walter Douthat,

Gabriela Cardozo,

Gabriela Garay,

Santiago Orozco,

Carlos Chiurchiu,

Jorge de la Fuente,

Javier de Arteaga,

P. Massari

Publication year - 2011

Publication title -

international journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.551

H-Index - 29

eISSN - 2090-2158

pISSN - 2090-214X

DOI - 10.4061/2011/246734

Subject(s) - medicine , percutaneous ethanol injection , parathyroidectomy , secondary hyperparathyroidism , hyperparathyroidism , surgery , urology , hypocalcaemia , calcium , parathyroid hormone , radiofrequency ablation , ablation

We evaluated the efficacy of percutaneous ethanol injection therapy (PEIT) as a therapeutic option for recurrence of secondary hyperparathyroidism after subtotal parathyroidectomy in ESRD patients. Six patients underwent PEIT. A mean of 1.3 ± 0.8 ethanol injections was performed. Nodular volume was 1.5 ± 1.7 cm3, and 2.8 ± 2.8 cm3 of ethanol was injected per patient. After ethanol injection PTH decreased significantly (1897 ± 754 to 549 ± 863 pg/mL (P<.01)). There was also a reduction in serum calcium, phosphorus and calcium-phosphorus product. A positive and significant correlation was found between nodular volume with ethanol injected and time from parathyroidectomy. Only one patient required hospitalization due to severe hypocalcaemia. In other two cases, local discomfort and temporary mild dysphonia were registered. PEIT is an effective treatment to control recurrences of secondary hyperparathyroidism postsubtotal parathyroidectomy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research